Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
E. Dann, R. Bar-Shalom, A. Tamir, N. Haim +8 more
Researcher profile · Semantic Scholar
E. Dann, R. Bar-Shalom, A. Tamir, N. Haim +8 more
M. Pick, V. Vainstein, N. Goldschmidt, D. Lavie +6 more
G. Spectre, D. Libster, S. Grisariu, N. Da’as +3 more
E. Dann, Z. Blumenfeld, R. Bar-Shalom, I. Avivi +6 more
Yossi Cohen, N. Da’as, D. Libster, G. Amir +2 more
Jacob Vine, Sara Cohen, R. Ruchlemer, N. Goldschmidt +7 more
N. Goldschmidt, G. Kleinstern, M. Orevi, O. Paltiel +5 more
Yossi Cohen, D. Libster, G. Amir, N. Hiller +3 more
Yossi Cohen, N. Daas, D. Libster, Dan Gillon +1 more
O. B. Katz, C. Perry, Sigal Grisariu Greenzaid, Dana Yehudai Ofir +16 more
V. Molho-Pessach, Ziad Agha, D. Libster, I. Lerer +4 more
S. Aumann, Uria Tsubary, B. Nachmias, D. Ben Yehuda +12 more
Adir Shaulov, C. Ganzel, N. Benyamini, Yossef Barshay +6 more
N. Goldschmidt, O. Paltiel, D. Ben Yehuda, G. Kleinstern +4 more
S. Aumann, Uria Tsubary, Sarah Israel, D. Ben Yehuda +12 more
Ofrat Beyar Katz, C. Perry, E. Luttwak, Inbal Sdayoor +16 more
B. Nachmias, Geremy Godefroy, C. Ganzel, N. Goldschmidt +4 more
Jacob Vine, Sara Cohen, R. Ruchlemer, N. Goldschmidt +7 more
E. Dann, Z. Blumenfeld, R. Bar-Shalom, I. Avivi +6 more
B. Chetaille, P. Finetti, B. Esterni, A. Stamatoullas +46 more
G. Spectre, D. Libster, S. Grisariu, N. Da’as +2 more